Looks like you’re on the UK site. Choose another location to see content specific to your location
Bristol-Myers Squibb names three new independent directors
Bristol-Myers Squibb has announced the appointment of three new independent directors, temporarily expanding the membership of its board to 14.
Robert Bertolini, Matthew Emmens and Theodore Samuels are all joining the board to provide the company with short-term expertise. The appointments follow discussions with JANA Partners, which became a Bristol-Myers Squibb shareholder in the fourth quarter of 2016.
The board will consist of 14 members until the company's 2017 annual meeting on May 2nd, where only 11 directors will stand for election. Lamberto Andreotti, chairman of the board, has previously confirmed that he will be retiring after this meeting.
Dr Giovanni Caforio, chief executive officer of Bristol-Myers Squibb, said: "Our new directors add important experience and skills managing large businesses and operations, broaden our overall expertise in the pharmaceutical sector and more broadly in capital markets, and complement extremely well the existing skills on our board."
Bristol-Myers Squibb also announced this week that it has entered into an accelerated share repurchase programme that will see it repurchase $2 billion (1.59 billion pounds) of its common stock in aggregate.
With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.
We have hundreds of jobs available across the Healthcare industry, find your perfect one now.
Stay informed
Receive the latest industry news, Tips
and straight to your inbox.
- Share Article
- Share on Twitter
- Share on Facebook
- Share on LinkedIn
- Copy link Copied to clipboard